Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study
British Journal of Dermatology2017Vol. 179(1), pp. 54–62
Citations Over TimeTop 10% of 2017 papers
G Schmieder, Zoé Kececioglu Draelos, David M. Pariser, Christopher Banfield, Lori Ann Cox, Martin R. Hodge, Elizabeth Kieras, Dana Parsons‐Rich, S. Menon, M.P. Salganik, Karen Page, E Peeva
Abstract
These results suggest that treatment with PF-04965842 improves symptoms and is well tolerated in patients with moderate-to-severe psoriasis.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment(2023)28 cited
- → Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)(2022)42 cited
- → Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis(2016)26 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited